Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases

Not yet recruiting

• Conditions: Pediatric Inflammatory Multisystem Syndrome; Myocarditis; Kawasaki Disease
• Interventions: Other: study of biological samples and echocardiographic data and link with need of hemodynamic support

• Registration Number: NCT05911386
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Acquired inflammatory or infectious cardiac diseases, in pediatrics, include Kawasaki disease, myocarditis, and Covid-19-related Pediatric Multisystemic Inflammatory Syndrome (PIMS).

These 3 inflammatory cardiac diseases have clinical, biological, and echographic similarities and differences. Nevertheless their modalities of monitoring, management and evolution are different. The investigators wish to retrospectively analyze biological and echocardiographic data of Kawasaki disease, myocarditis, PIMS patients managed at Nancy Children Hospital from January 1, 2017 to June 31, 2023.

The primary objective of this study is to identify, for these 3 pathologies, the prognostic factors of initiation of inotropic support.

The secondary objective is to identify the prognostic factors of degradation of ventricular function.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-09
• Study First Submitted QC: 2023-06-20
• Study First Posted: 2023-06-22
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-29
• Last Update Posted: 2023-08-30
• Study Start: 2023-09
• Primary Completion: 2023-09
• Study Completion: 2023-09

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• diagnostic of PIMS, myocarditis or kawasaki disease patients
• age < 18 years

Exclusion Criteria

• uncertain diagnosis
• other complex heart disease
• management out of Nancy University children hospital center

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
MYOCARDITIS	study of biological samples and echocardiographic data and link with need of hemodynamic support	No intervention Study of available clinical, biological, and echocardiographic data
PIMS	study of biological samples and echocardiographic data and link with need of hemodynamic support	No intervention Study of available clinical, biological, and echocardiographic data
KAWASAKI	study of biological samples and echocardiographic data and link with need of hemodynamic support	No intervention Study of available clinical, biological, and echocardiographic data

Primary Outcome Measures

Name	Time	Method
need of hemodynamic support	up to 20 days	The need for haemodynamic support is defined dichotomously: yes or no. The investigators wish to identify the predictive factors of need for haemodynamic support among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction, global and regional longitudinal strain at admission (in %)).

Secondary Outcome Measures

Name	Time	Method
deterioration of Left Ventricular Ejection fraction	up to 20 days	Left Ventricular Ejection fraction degradation is defined as an Left Ventricular Ejection fraction below the value of the first quartile of Left Ventricular Ejection fraction of all patients taken into account (Left Ventricular Ejection fraction as a percentage).; The investigators wish to identify the predictive factors of Left Ventricular Ejection fraction degradation among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction , global and regional longitudinal strain at admission (in %)).

Trial Locations

Locations (1)

Gilles BOSSER; 🇫🇷 Vandœuvre-lès-Nancy, France